umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Alternative names
Publications (10 of 10) Show all publications
Tyler, A. (2016). Targeting Gb3 and apoptosis-related proteins to overcome cisplatin resistance. (Doctoral dissertation). Umeå: Umeå Universitet
Open this publication in new window or tab >>Targeting Gb3 and apoptosis-related proteins to overcome cisplatin resistance
2016 (English)Doctoral thesis, comprehensive summary (Other academic)
Alternative title[sv]
Gb3 och apoptos-relaterade proteiner som måltavla för att bryta cisplatinresistens
Abstract [en]

Background Cisplatin is used for treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) but treatment with cisplatin often leads to acquired resistance to cisplatin, resulting in poor patient survival. Globotriaosylceramide (Gb3) and multidrug resistance protein 1 (MDR1) have been associated with cisplatin resistance. Gb3 serves as a receptor for verotoxin-1 (VT-1), which induces apoptosis, and has been shown to have a functional dependency to MDR1 and heat shock protein 70 (HSP7o). The Bcl-2 family of proteins and inhibitors of apoptosis (IAPs) are key regulators of apoptosis. BH3-mimetics mimic pro-apoptotic BH3-only proteins, while Smac mimetics mimic the IAP-binding protein Smac/Diablo. These drugs have shown great promise in reversing cisplatin resistance. Exosomes are small bio-nanoparticles secreted and taken up by both cancer cells and normal cells. They have the ability to transfer properties between cells and have been shown to confer resistance to cisplatin.

Methods In this thesis, NSCLC cell line H1299 and MPM cell line P31 were studied using western blot, flow cytometry, proteome profilers, confocal microscopy and gene expression arrays to investigate changes in protein and gene expression after acquisition of cisplatin resistance (P31res and H1299res) or after incubation with exosomes or drugs that target these. The cytotoxic and apoptotic effects were studied using fluorometric cytotoxicity assay (FMCA) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay.

Results This thesis confirms that Gb3 is a potential target for cisplatin resistance reversal. Incubation with glycosphingolipid production inhibitor DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) and VT-1 led to reduced Gb3 cell surface expression and increased cytotoxic effect of cisplatin in all cell lines. Gb3 and MDR1 was not co-localized in any studied cell line, but Gb3 and HSP70 were co-localized on the cell surface and PPMP and VT-1 led to a decrease of both Gb3 and HSP70. Both BH3-mimetic obatoclax and Smac mimetic AT-406 had an additive effect on cisplatin-induced cytotoxicity and apoptosis in P31 and a synergistic effect in P31res. Results indicate that exosomes from cisplatin-resistant cell lines can transfer HSP70 to the surface of cells.

Conclusion Cell surface Gb3 and HSP70, the Bcl-2/IAP-family proteins and exosomal transfer of cisplatin resistance characteristics are potential targets in combatting cisplatin resistance that show therapeutic promise and warrant further research.

Place, publisher, year, edition, pages
Umeå: Umeå Universitet, 2016. p. 48
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 1807
Keywords
Cisplatin resistance, exosomes, gb3, HSP70, the Bcl-2 family
National Category
Cell and Molecular Biology
Research subject
cell research; Medical Cell Biology; Oncology
Identifiers
urn:nbn:se:umu:diva-119778 (URN)978-91-7601-475-2 (ISBN)
Public defence
2016-05-23, E04, By 6E, Nod R, Norrlands universitetssjukhus, 901 85 Umeå, Umeå, 13:00 (English)
Opponent
Supervisors
Funder
Swedish Cancer Society, CAN 2011/599
Available from: 2016-05-02 Created: 2016-04-26 Last updated: 2018-06-07Bibliographically approved
Tyler, A., Johansson, A., Karlsson, T., Kumar Gudey, S., Brännström, T., Grankvist, K. & Behnam-Motlagh, P. (2015). Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells. Experimental Cell Research, 336(1), 23-32
Open this publication in new window or tab >>Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells
Show others...
2015 (English)In: Experimental Cell Research, ISSN 0014-4827, E-ISSN 1090-2422, Vol. 336, no 1, p. 23-32Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Acquired resistance to cisplatin treatment is a caveat when treating patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Ceramide increases in response to chemotherapy, leading to proliferation arrest and apoptosis. However, a tumour stress activation of glucosylceramide synthase (GCS) follows to eliminate ceramide by formation of glycosphingolipids (GSLs) such as globotriaosylceramide (Gb3), the functional receptor of verotoxin-1. Ceramide elimination enhances cell proliferation and apoptosis blockade, thus stimulating tumor progression. GSLs transactivate multidrug resistance 1/P-glycoprotein (MDR1) and multidrug resistance-associated protein 1 (MRP1) expression which further prevents ceramide accumulation and stimulates drug efflux. We investigated the expression of Gb3, MDR1 and MRP1 in NSCLC and MPM cells with acquired cisplatin resistance, and if GCS activity or MDR1 pump inhibitors would reduce their expression and reverse cisplatin-resistance.

METHODS: Cell surface expression of Gb3, MDR1 and MRP1 and intracellular expression of MDR1 and MRP1 was analysed by flow cytometry and confocal microscopy on P31 MPM and H1299 NSCLC cells and subline cells with acquired cisplatin resistance. The effect of GCS inhibitor PPMP and MDR1 pump inhibitor cyclosporin A for 72h on expression and cisplatin cytotoxicity was tested.

RESULTS: The cisplatin-resistant cells expressed increased cell surface Gb3. Cell surface Gb3 expression of resistant cells was annihilated by PPMP whereas cyclosporin A decreased Gb3 and MDR1 expression in H1299 cells. No decrease of MDR1 by PPMP was noted in using flow cytometry, whereas a decrease of MDR1 in H1299 and H1299res was indicated with confocal microscopy. No certain co-localization of Gb3 and MDR1 was noted. PPMP, but not cyclosporin A, potentiated cisplatin cytotoxicity in all cells.

CONCLUSIONS: Cell surface Gb3 expression is a likely tumour biomarker for acquired cisplatin resistance of NSCLC and MPM cells. Tumour cell resistance to MDR1 inhibitors of cell surface MDR1 and Gb3 could explain the aggressiveness of NSCLC and MPM. Therapy with GCS activity inhibitors or toxin targeting of the Gb3 receptor may substantially reduce acquired cisplatin drug resistance of NSCLC and MPM cells.

Keywords
Cisplatin,  Glucosylceramide synthase (GCS),  Globotriaosylceramide (Gb3),  Lung cancer,  Multidrug resistance 1/P-glycoprotein (MDR1), Multidrug resistance-associated protein 1 (MRP1),  Malignant pleural mesothelioma (MPM),  DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP),  Cyclosporin A,  Acquired drug resistance
National Category
Medical Biotechnology
Identifiers
urn:nbn:se:umu:diva-103786 (URN)10.1016/j.yexcr.2015.05.012 (DOI)000358821700003 ()26004871 (PubMedID)
Funder
Swedish Cancer Society
Available from: 2015-05-30 Created: 2015-05-30 Last updated: 2018-06-07Bibliographically approved
Wu, C., Wang, S., Xu, C., Tyler, A., Li, X., Andersson, C., . . . Li, A. (2015). WT1 Enhances Proliferation and Impedes Apoptosis in KRAS Mutant NSCLC via Targeting cMyc. Cellular Physiology and Biochemistry, 35(2), 647-662
Open this publication in new window or tab >>WT1 Enhances Proliferation and Impedes Apoptosis in KRAS Mutant NSCLC via Targeting cMyc
Show others...
2015 (English)In: Cellular Physiology and Biochemistry, ISSN 1015-8987, E-ISSN 1421-9778, Vol. 35, no 2, p. 647-662Article in journal (Refereed) Published
Abstract [en]

Background: A novel link between oncogenic KRAS signalling and WT1 was recently identified. We sought to investigate the role of WT1 and KRAS in proliferation and apoptosis. Methods: KRAS mutations and WT1 (cMyc) expression were detected using Sanger sequencing and real-time PCR in 77 patients with non-small cell lung cancer (NSCLC). Overexpression and knockdown of WT1 were generated with plasmid and siRNA via transient transfection technology in H1299 and H1568 cells. MTT assay for detection of cell proliferation, and TUNEL assay amd proteomic profiler assay for apoptosis evaluation were carried out. Dual luciferase reporter assay and ChIP-PCR were performed to validate the effect of WT1 on the cMyc promoter. Results: KRAS mutations showed a negative impact on overall survival ( OS). High expressions of WT1 and cMyc were associated with poor OS in KRAS mutant subgroup. The potential mechanisms that WT1 promotes proliferation and impedes apoptosis through affecting multiple apoptosis-related regulators in KRAS mutant NSCLC cells were identified. WT1 could activate cMyc promoter directly in KRAS mutant cells. Conclusion: The results suggest that WT1 and c-MYC expression is important for survival in KRAS mutant tumors as opposed to KRAS wild-type tumors. For treatment of KRAS mutant NSCLC, targeting WT1 and cMyc may provide alternative therapeutic strategies.

Keywords
KRAS mutation, WT1, cMyc, NSCLC, Apoptosis
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:umu:diva-100786 (URN)10.1159/000369726 (DOI)000349032700019 ()25613309 (PubMedID)
Available from: 2015-03-11 Created: 2015-03-09 Last updated: 2018-06-07Bibliographically approved
Behnam-Mothlag, P., Tyler, A., Brännström, T., Karlsson, T., Johansson, A. & Grankvist, K. (2012). Cisplatin Resistance in Malignant Pleural Mesothelioma. In: Alexander Zubritsky (Ed.), Mesotheliomas: Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis (pp. 169-186). Zagreb: InTech, 11
Open this publication in new window or tab >>Cisplatin Resistance in Malignant Pleural Mesothelioma
Show others...
2012 (English)In: Mesotheliomas: Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis / [ed] Alexander Zubritsky, Zagreb: InTech, 2012, Vol. 11, p. 169-186Chapter in book (Refereed)
Place, publisher, year, edition, pages
Zagreb: InTech, 2012
Keywords
Mesothelioma, drug resistance, bacterial toxins
National Category
Medical and Health Sciences
Research subject
Oncology
Identifiers
urn:nbn:se:umu:diva-54085 (URN)10.5772/31685 (DOI)978-953-307-845-8 (ISBN)
Available from: 2012-05-11 Created: 2012-04-15 Last updated: 2018-06-08Bibliographically approved
Behnam Motlagh, P., Tyler, A., Johansson, A., Brännstrom, T. & Grankvist, K. (2011). Co-expression of Globotriasosylceramide (Gb3) With MDR1 in Cisplatin-resistant Pleural Mesothelioma and Non-small Cell Lung Cancer Cell May Lead to a New Tumour Resistance Treatment Approach. Paper presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, September 23-27 2011. Oxford: Pergamon, 47
Open this publication in new window or tab >>Co-expression of Globotriasosylceramide (Gb3) With MDR1 in Cisplatin-resistant Pleural Mesothelioma and Non-small Cell Lung Cancer Cell May Lead to a New Tumour Resistance Treatment Approach
Show others...
2011 (English)Conference paper, Published paper (Refereed)
Place, publisher, year, edition, pages
Oxford: Pergamon, 2011
Series
European Journal of Cancer, ISSN 0959-8049 ; Vol. 47 Suppl. 1
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-49260 (URN)10.1016/S0959-8049(11)72336-X (DOI)000295752802130 ()
Conference
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, September 23-27 2011
Available from: 2011-11-09 Created: 2011-11-04 Last updated: 2018-06-08Bibliographically approved
Tyler, A., Jansson, V., Behnam Motlagh, P., Johansson, A. & Grankvist, K. (2011). Effect of BH3-mimetics GX15-070 and ABT-737 on cisplatin resistance in malignant pleural mesothelioma cells. Paper presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, September 23-27 2011. Oxford: Pergamon, 47
Open this publication in new window or tab >>Effect of BH3-mimetics GX15-070 and ABT-737 on cisplatin resistance in malignant pleural mesothelioma cells
Show others...
2011 (English)Conference paper, Published paper (Refereed)
Place, publisher, year, edition, pages
Oxford: Pergamon, 2011
Series
European Journal of Cancer ; Vol. 47 Suppl. 1
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-49261 (URN)10.1016/S0959-8049(11)72336-X (DOI)000295752802131 ()
Conference
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, September 23-27 2011
Available from: 2011-11-09 Created: 2011-11-04 Last updated: 2018-06-08Bibliographically approved
Behnam-Motlagh, P., Tyler, A., Grankvist, K. & Johansson, A. (2010). Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy. Toxins, 2(10), 2467-2477
Open this publication in new window or tab >>Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy
2010 (English)In: Toxins, ISSN 2072-6651, Vol. 2, no 10, p. 2467-2477Article, review/survey (Refereed) Published
Abstract [en]

A major problem with anti-cancer drug treatment is the development of acquired multidrug resistance (MDR) of the tumor cells. Verotoxin-1 (VT-1) exerts its cytotoxicity by targeting the globotriaosylceramide membrane receptor (Gb3), a glycolipid associated with multidrug resistance. Gb3 is overexpressed in many human tumors and tumor cell lines with inherent or acquired MDR. Gb3 is co-expressed and interplays with the membrane efflux transporter P-gp encoded by the MDR1 gene. P-gp could act as a lipid flippase and stimulate Gb3 induction when tumor cells are exposed to cancer chemotherapy. Recent work has shown that apoptosis and inherent or acquired multidrug resistance in Gb3-expressing tumors could be affected by VT-1 holotoxin, a sub-toxic concentration of the holotoxin concomitant with chemotherapy or its Gb3-binding B-subunit coupled to cytotoxic or immunomodulatory drug, as well as chemical manipulation of Gb3 expression. The interplay between Gb3 and P-gp thus gives a possible physiological approach to augment the chemotherapeutic effect in multidrug resistant tumors.

Place, publisher, year, edition, pages
Basel: MDPI, 2010
Keywords
apoptosis, cancer, Gb3, verotoxin-1, multi-drug resistance, MDR1, P-gp
National Category
Cancer and Oncology
Research subject
cell research
Identifiers
urn:nbn:se:umu:diva-40654 (URN)10.3390/toxins2102467 (DOI)000208435600007 ()
Available from: 2011-03-07 Created: 2011-03-03 Last updated: 2018-06-08Bibliographically approved
Tyler, A., Sandberg, C., Blom, A., Johansson, A., Behnam-Motlagh, P., Rondahl, V. & Grankvist, K.Acquired cisplatin resistance in malignant pleural mesothelioma cells is reversed by both BH3-mimetic obatoclax and IAP-inhibitor AT-406.
Open this publication in new window or tab >>Acquired cisplatin resistance in malignant pleural mesothelioma cells is reversed by both BH3-mimetic obatoclax and IAP-inhibitor AT-406
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Treatment of malignant pleural mesothelioma (MPM) with cisplatin often leads to acquired resistance with ensuing therapy failure, which may be the consequence of decreased apoptosis due overexpression of anti-apoptotic Bcl-2 family proteins or inhibitor of apoptosis (IAP) family proteins. Pro-apoptotic BH3-mimetics that antagonize the anti-apoptotic Bcl-2 protein family members and IAP inhibitors, which target the IAP family, could re-sensitize resistant MPM cells to cisplatin. We studied the effects of cisplatin, IAP inhibitor AT-406 and the BH3-mimetics ABT-737 and obatoclax on apoptosis and cytotoxicity in a cisplatin-resistant subline of MPM (P31res) and its parental cell line (P31). We used protein arrays and Western blot to study the differences between P31 and P31res cells in apoptosis signal transduction as well as the effects of cisplatin and obatoclax . P31res cells displayed changes in the Bcl-2 family protein expression in response to cisplatin and a massive inhibition of Bcl-x expression by obatoclax. The IAP-binding proteins Smac/Diablo and Htra2 were downregulated in P31res cells and cisplatin further downregulated Htra2. This suggested that Bcl-2 family proteins and IAP-related proteins may play a role in cisplatin resistance in the studied cell lines. Obatoclax decreased IAP protein expression in both P31 and P31res subline cells but addition of cisplatin abolished this effect in P31res cells. The IAP inhibitor AT-406 and BH3-mimetic obatoclax increased cisplatin cytotoxicity and apoptosis. Combined use of obatoclax with IAP inhibition only had a slight additive effect. This warrants further studies of targeting anti-apoptotic Bcl-2 family proteins and IAPs in malignant pleural mesothelioma. 

Keywords
Obatoclax, ABT-737, cisplatin, acquired drug resistance, inhibitors of apoptosis, malignant mesothelioma
National Category
Cell and Molecular Biology
Research subject
cell research; Medical Cell Biology; Oncology
Identifiers
urn:nbn:se:umu:diva-119774 (URN)
Funder
Swedish Cancer Society
Available from: 2016-04-27 Created: 2016-04-26 Last updated: 2018-06-07Bibliographically approved
Tyler, A., Johansson, A., Lundholm, M., Rodsand, P., Karlsson, T., Grankvist, K. & Behnam-Motlagh, P.Cell membrane expression of HSP70 in cisplatin resistant tumour cells may be targeted through the co-localized glycosphingolipid Gb3.
Open this publication in new window or tab >>Cell membrane expression of HSP70 in cisplatin resistant tumour cells may be targeted through the co-localized glycosphingolipid Gb3
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Globotriaosylceramide (Gb3) and heat-shock protein 70 (HSP70) are often co-localized on the cell surface of tumours and facilitates metastasis and cisplatin resistance. We hypothesized that targeting Gb3 could also inhibit HSP70 expression in non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM).

Gb3 and HSP70 were co-localized on the cell surface. The glucosylceramide synthaseinhibitor DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP), Gb3 synthase siRNA and VT-1 reduced Gb3 and HSP70 expression, while HSP90-inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) increased Gb3 and HSP70. The combination of 17-AAG and VT-1 had a synergistic cytotoxic effect.

Cell membrane HSP70 expression in cisplatin-resistant tumour cells may be targeted through co-localized Gb3. 

Keywords
Globotriaosylceramide, heat shock protein 70, cisplatin, verotoxin-1, glycosphingolipid, glucosylceramide synthase
National Category
Cell and Molecular Biology
Research subject
cell research; Medical Cell Biology; Oncology
Identifiers
urn:nbn:se:umu:diva-119786 (URN)
Funder
Swedish Cancer Society, CAN 2011/599
Available from: 2016-04-27 Created: 2016-04-27 Last updated: 2018-06-07Bibliographically approved
Tyler, A., Johansson, A., Karlsson, T., Rodsand, P., Lundholm, M., Grankvist, K. & Behnam-Motlagh, P.The role of exosomes in transferal of acquired cisplatin resistance.
Open this publication in new window or tab >>The role of exosomes in transferal of acquired cisplatin resistance
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Background: A major obstacle when treating cancer patients with cisplatin is that cancer often acquires cisplatin resistance during treatment, resulting in poor patient survival time. One important mechanism of cisplatin resistance is thought to be transferal of pro-survival characteristics, such as increased expression of the anti-apoptotic heat shock protein 70 (HSP70) through release and uptake of exosomes, small bioparticles that contain proteins, messenger RNA (mRNA) or micro RNA (miR).

Methods: We studied the morphology and size distribution of exosomes released by malignant pleural mesothelioma (MPM) and non-small cell lung cancer cells through confocal microscopy and nanoparticle tracking analysis. We assessed whether exosomes extracted from cells of the studied cell lines could fuse with the plasma membrane and introduce HSP70 to the cell surface through confocal microscopy.

Results: Exosomes secreted from cisplatin-resistant P31res cells and H1299res cells were able to fuse with the plasma membrane and present HSP70 on the surface of cells from the corresponding cell line (P31 and H1299) as well as the cells they originated from.

Conclusions: Cisplatin resistance transferal through exosomes may lead to better future treatment alternatives.

Keywords
Cisplatin, acquired drug resistance, exosomes, globotriaosylceramide (Gb3), heat shock protein 70 (HSP70)
National Category
Cell and Molecular Biology
Research subject
cell research; Medical Cell Biology; Oncology
Identifiers
urn:nbn:se:umu:diva-119775 (URN)
Funder
Swedish Cancer Society, CAN 2011/599
Available from: 2016-04-27 Created: 2016-04-26 Last updated: 2018-06-07Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-4968-6192

Search in DiVA

Show all publications